Ligand Pharmaceuticals exceeded Q earnings estimates with $3.84 EPS and $30.9m revenue.
Ligand Pharmaceuticals (LGND) surpassed Q earnings estimates with $3.84 EPS, compared to $0.83, and $30.9m revenue vs. $27.9m. Despite a 29.8% year-over-year revenue decline, the biopharma firm's shares rose to $73.22. Benchmark and HC Wainwright maintain "buy" ratings, with target prices of $95.00 and $144.00, respectively. LGND's commercial programs include Kyprolis, Evomela, Rylaze, and more.
May 07, 2024
3 Articles